Form 4: Day One Bio Grants Equity to Head of R&D

Day One Biopharmaceuticals, Inc. granted stock options and restricted stock units to its Head of Research and Development, Michael Vasconcelles.

Summary

• Michael Vasconcelles, Head of Research and Development at Day One Biopharmaceuticals, Inc. (DAWN), was granted 171,000 stock options and 114,000 Restricted Stock Units (RSUs).
• The stock options have an exercise price of $11.16 and vest as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to continued service, and expire on January 29, 2036.
• The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies the company's commitment to retaining and incentivizing key R&D leadership, which is crucial for a biopharmaceutical company's long-term success.

Positives

• The grant of stock options and restricted stock units aligns the interests of the Head of Research and Development, Michael Vasconcelles, with those of shareholders, incentivizing long-term performance.
• This compensation package is a standard mechanism for retaining key executive talent in the biotechnology sector.

Negatives

• The issuance of new equity awards could lead to potential dilution for existing shareholders if all options are exercised and RSUs vest, though this is a common practice for executive compensation.

Future Outlook

The vesting schedules for the granted stock options and Restricted Stock Units extend through January 2036, indicating a long-term incentive structure for the Head of Research and Development, aligning future performance with compensation.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and Restricted Stock Units, are a standard and widely adopted practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key scientific and executive talent. This practice is crucial for companies like Day One Biopharmaceuticals, Inc., which rely heavily on long-term research and development efforts.

Comparison to Industry Standards

• The structure of equity compensation, including both stock options and RSUs with multi-year vesting schedules, is consistent with typical executive compensation packages observed in comparable biotech firms.
• For instance, similar grants are common at companies like BioNTech SE or Moderna, Inc., where R&D leadership is critical, often involving a mix of performance-based and time-based equity awards to ensure long-term commitment and alignment with shareholder value.

Related Party Transactions

• The grant of 171,000 stock options and 114,000 Restricted Stock Units to Michael Vasconcelles, Head of Research and Development, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized executive performance, balanced against potential future dilution from option exercise and RSU settlement.
• Employees: May signal stability and a commitment to long-term R&D strategy, potentially boosting morale.
• Management: Provides significant long-term incentive and compensation, aligning personal financial interests with company performance.

Next Steps

• Monthly vesting of 1/48th of stock options commencing February 28, 2026.
• Quarterly vesting of 1/16th of Restricted Stock Units on February 15, May 15, August 15, and November 15.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the company's valuation or strategic outlook to warrant a change in investment recommendation. It reinforces a 'hold' stance, acknowledging the ongoing efforts to retain talent without providing a strong catalyst for significant price movement.

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Grant, Executive Compensation, Michael Vasconcelles, Biotechnology